Earnings call briefThird-quarter 2026
Regeneron Pharmaceuticals expects 2027 R&D expense to rise by mid-teens percentage
Chief Financial Officer Christopher R. Fenimore also said the company expects full-year share repurchases to total approximately $3 billion.
GetSignal Regeneron Pharmaceuticals REGN
Regeneron Pharmaceuticals said on its third-quarter call that it currently expects 2027 R&D expense to increase by a mid-teens percentage compared with 2026, to support its pipeline progress.
Marion McCourt, Executive Vice President, Commercial, said the company expects full-year EYLEA HD net sales growth of over 50% compared with 2025.
Quotes from the call
“...we currently expect 2027 R&D expense to increase by a mid teens percentage compared with 2026.”
“We expect full year share repurchases to total approximately $3 billion.”
Key facts from the call
- Expected 2027 R&D expense change
- Increase by a mid-teens percentage compared with 2026
- Expected full-year share repurchases
- Approximately $3 billion
- Expected full-year EYLEA HD net sales growth
- Over 50% compared with 2025
Source: Regeneron Pharmaceuticals' third-quarter 2026 earnings call, October 30, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
